AVITA Medical, Inc.

RCEL

AVITA Medical, Inc.

RCEL

Insider Sentiment (TTM):

Last Purchase:2026-06-09Last Sale:2023-12-26Shares Purchased (TTM):44,000Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:46,276,871Shares Outstanding:30,540,872Institutional Ownership Pct.:151.52%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	9	8	10	15	12	15	14	19	17	17	22	51
Marketable Securities Current	2	6	8	8	3	11	22	26	37	51	67	9
Accounts Receivable Net Current	10	10	9	9	11	9	12	10	9	7	8	6
Prepaid Expense And Other Assets Current	2	1	1	2	2	2	2	3	3	4	2	3
Other Receivables Net Current	-	-	-	-	-	-	0	0	0	0	0	0
F I F O Inventory Amount	5	6	7	7	8	8	7	6	7	7	6	4
Assets Current	28	32	35	41	36	48	57	64	73	86	104	74
Property Plant And Equipment Net	8	8	9	10	10	10	10	9	7	4	2	2
Operating Lease Right Of Use Asset	3	3	3	3	3	3	4	4	4	3	2	3
Intangible Assets Net Excluding Goodwill	5	5	6	5	5	5	6	1	1	1	0	0
Other Assets Noncurrent	1	1	1	1	1	0	1	1	0	0	0	0
Assets	48	52	56	64	58	70	80	81	88	97	112	81
Liabilities And Stockhold…
Accounts Payable And Accrued Liabilities Current	6	7	9	8	7	9	6	4	4	4	4	3
Long Term Debt Current	47	46	43	42	-	-	0	-	-	-	-	-
Business Combination Contingent Consideration Liab…	3	3	-	3	3	3	-	-	-	-	-	-
Other Liabilities Current	3	2	3	2	2	2	1	1	1	1	1	1
Liabilities Current	69	67	63	62	63	23	20	17	14	12	13	12
Long Term Debt Noncurrent	-	-	0	0	42	41	42	43	41	41	40	-
Contract With Customer Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	2	2	2	2	2	3	3	3	3	3	2	2
Asset Acquisition Contingent Consideration Liabili…	0	0	3	0	0	0	3	-	-	-	-	-
Liabilities	76	75	73	70	71	74	75	69	64	64	62	17
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Value	0	0	0	0	0	0	0	-	-	0	0	0
Additional Paid In Capital	400	396	394	393	374	371	368	364	359	353	350	347
Accumulated Other Comprehensive Income Loss Net Of…	-0	1	-1	-1	-2	-0	-2	-2	-2	-3	-2	8
Retained Earnings Accumulated Deficit	-427	-419	-408	-397	-384	-374	-360	-348	-332	-317	-298	-291
Stockholders Equity	-28	-23	-17	-7	-13	-5	4	12	24	33	49	63
Liabilities And Stockholders Equity	48	52	56	64	58	70	80	81	88	97	112	81
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	31	31	31	30	27	26	26	26	26	26	26	26
Shares Outstanding	31	31	31	30	27	26	26	26	26	26	26	26
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-4.13%	16.06%	0.92%	-	-	-	-	-	-	-	-	-
2025	-39.76%	-41.59%	-38.16%	2.12%	22.35%	-6.59%	8.82%	1.18%	30.59%	27.69%	-0.27%	19.35%
2024	9.58%	-3.35%	-1.20%	18.03%	35.44%	27.74%	3.39%	8.79%	-24.84%	-5.47%	-14.58%	5.24%
2023	-	-	-	-10.78%	-20.03%	-49.15%	13.77%	38.87%	68.32%	-3.41%	-41.92%	-51.44%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.41	0.47	0.57	0.67	0.58	2.09	2.83	3.73	5.29	7.25	7.88	6.25
Quick Ratio	0.38	0.45	0.55	0.64	0.55	2.02	2.73	3.56	5.05	6.95	7.75	5.96
Working Capital	-40.32M	-35.02M	-27.19M	-20.46M	-26.35M	25.01M	36.84M	46.78M	59.17M	74.12M	90.81M	62.09M
Leverage & Debt
Debt to Equity	-2.72	-3.22	-4.39	-10.56	-5.51	-16.20	16.66	5.61	2.66	1.96	1.26	0.28
Interest Coverage TTM	-6.51	-7.61	-8.50	-8.33	-9.09	-9.78	-10.56	-11.36	-14.19	-20.02	-37.32	-1,344.07
Debt Ratio	1.58	1.45	1.30	1.10	1.22	1.06	0.94	0.85	0.72	0.66	0.55	0.21
Efficiency & Turnover
Asset Turnover TTM	1.41	1.18	1.04	0.99	1.02	0.85	0.67	0.87	0.74	0.64	0.58	0.50
Days Sales Outstanding TTM	51.69	48.38	53.74	49.15	49.37	41.53	55.56	41.88	40.83	34.51	33.61	37.90
Receivables Turnover TTM	7.06	7.54	6.79	7.43	7.39	8.79	6.57	8.71	8.94	10.58	10.86	9.63
Per Share Metrics
Diluted EPS TTM	-1.40	-1.48	-1.74	-1.71	-1.96	-2.17	-2.39	-2.21	-1.93	-1.75	-1.40	-1.33
Free Cash Flow Per Share TTM	-0.84	-1.07	-1.19	-0.94	-1.19	-1.78	-2.25	-2.29	-2.25	-2.03	-1.56	-1.25
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	82.37%	82.19%	82.98%	84.61%	85.11%	86.13%	86.33%	73.03%	72.06%	70.32%	69.80%	83.85%
Operating Profit Margin TTM	-47.03%	-55.17%	-60.01%	-58.73%	-63.03%	-72.02%	-88.57%	-83.65%	-84.12%	-81.56%	-70.28%	-79.93%
Net Profit Margin TTM	-57.53%	-63.31%	-68.55%	-67.76%	-69.55%	-80.22%	-96.79%	-81.39%	-77.04%	-73.18%	-58.30%	-74.16%
Growth Metrics
Net Revenue Growth (1Y)	0.98%	0.71%	10.93%	1.75%	14.66%	16.11%	5.27%	55.11%	58.33%	63.62%	76.33%	41.95%
Net Income Growth (1Y)	-16.46%	-20.52%	-21.44%	-15.29%	3.50%	27.28%	74.80%	70.25%	63.13%	69.63%	32.69%	23.51%
EPS Growth (1Y)	-28.37%	-31.68%	-27.01%	-22.48%	1.12%	24.30%	71.07%	66.43%	59.83%	66.74%	30.95%	21.59%
Valuation Metrics
P/E TTM	-2.95	-2.49	-1.98	-2.99	-2.70	-3.75	-5.36	-4.86	-4.09	-9.17	-9.82	-11.02
P/B TTM	-4.56	-4.88	-5.77	-21.77	-10.82	-46.75	73.64	22.78	8.53	12.62	7.08	5.89
P/S TTM	1.70	1.58	1.36	2.02	1.88	3.01	5.19	3.96	3.15	6.71	5.73	8.17
Market Cap	127.00M	113.00M	96.12M	145.09M	139.48M	213.70M	331.30M	278.55M	204.02M	410.97M	347.54M	371.12M
Enterprise Value	164.52M	150.83M	128.86M	172.12M	169.48M	240.30M	359.50M	302.46M	227.56M	435.32M	365.24M	320.27M
Calculated Values
Free Cash Flow TTM	-25.96M	-32.67M	-33.11M	-26.60M	-31.42M	-46.63M	-58.11M	-59.58M	-58.08M	-52.05M	-39.39M	-31.74M
Net Debt	37.52M	37.83M	32.74M	27.03M	30.00M	26.59M	28.20M	23.91M	23.54M	24.35M	17.69M	-50.85M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-09Purchase

Owner: Woody, Joseph Fralin

Title: -

Shares: 5,200

Price/Share: $4.00

Value: $20,800.00

Shares Owned: 107,961

Relationship: Director

Ownership: Direct

2026-06-03Purchase

Owner: Woody, Joseph Fralin

Title: -

Shares: 10,000

Price/Share: $4.10

Value: $41,000.00

Shares Owned: 92,761

Relationship: Director

Ownership: Direct

2026-06-02Purchase

Owner: Woody, Joseph Fralin

Title: -

Shares: 10,000

Price/Share: $4.20

Value: $42,000.00

Shares Owned: 20,000

Relationship: Director

Ownership: Direct

2026-05-20Purchase

Owner: O'Toole, David D

Title: CFO

Shares: 2,000

Price/Share: $4.26

Value: $8,520.00

Shares Owned: 145,927

Relationship: Officer

Ownership: Direct

2026-05-19Purchase

Owner: O'Toole, David D

Title: CFO

Shares: 2,000

Price/Share: $4.24

Value: $8,480.00

Shares Owned: 143,927

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-09	Woody, Joseph Fralin	Director	-	Direct	Purchase	5,200	4.00	$20,800.00	107,961	4
2026-06-03	Woody, Joseph Fralin	Director	-	Direct	Purchase	10,000	4.10	$41,000.00	92,761	4
2026-06-02	Woody, Joseph Fralin	Director	-	Direct	Purchase	10,000	4.20	$42,000.00	20,000	4
2026-05-20	O'Toole, David D	Officer	CFO	Direct	Purchase	2,000	4.26	$8,520.00	145,927	4
2026-05-19	O'Toole, David D	Officer	CFO	Direct	Purchase	2,000	4.24	$8,480.00	143,927	4
2026-03-11	O'Toole, David D	Officer	CFO	Direct	Purchase	1,800	4.78	$8,604.00	141,927	4
2026-02-19	O'Toole, David D	Officer	CFO	Direct	Purchase	3,000	4.15	$12,450.00	140,127	4
2025-08-28	Mcnamara, Robert	Director	-	Direct	Purchase	10,000	4.50	$45,000.00	86,771	4
2025-08-26	O'Toole, David D	Officer	CFO	Direct	Purchase	2,000	4.52	$9,040.00	31,657	4
2025-08-19	Mcnamara, Robert	Director	-	Direct	Purchase	10,000	5.00	$50,000.00	76,771	4
2025-08-12	O'Toole, David D	Officer	CFO	Direct	Purchase	2,000	4.81	$9,620.00	29,657	4
2025-03-06	Mcnamara, Robert	Director	-	Direct	Purchase	11,000	8.30	$91,300.00	56,749	4
2025-02-20	Mcnamara, Robert	Director	-	Direct	Purchase	10,000	10.09	$100,900.00	45,749	4
2025-02-20	O'Toole, David D	Officer	CFO	Direct	Purchase	1,000	9.90	$9,900.00	25,734	4
2025-02-19	O'Toole, David D	Officer	CFO	Direct	Purchase	1,000	10.25	$10,250.00	24,734	4
2024-12-09	Crowe, Suzanne	Director	-	Direct	Purchase	486	13.15	$6,390.90	36,912	4
2024-12-05	O'Toole, David D	Officer	CFO	Direct	Purchase	975	12.46	$12,148.50	23,734	4
2024-05-30	O'Toole, David D	Officer	CFO	Direct	Purchase	1,000	8.90	$8,900.00	19,734	4
2024-02-28	O'Toole, David D	Officer	CFO	Direct	Purchase	1,250	17.40	$21,750.00	18,734	4
2023-12-26	Corbett, James	Director,Officer	CEO	Direct	Sale	1,445	13.29	$19,204.05	11,580	4
2023-12-21	Cook, Jeremy Curnock	Director	-	Direct	Sale	2,500	12.49	$31,225.00	20,614	4/A
2023-12-13	Cook, Jeremy Curnock	Director	-	Direct	Sale	2,518	12.27	$30,895.86	20,596	4
2023-12-12	O'Toole, David D	Officer	CFO	Direct	Purchase	950	12.45	$11,827.50	17,484	4
2023-12-01	O'Toole, David D	Officer	CFO	Direct	Purchase	500	10.68	$5,340.00	16,534	4
2023-11-21	O'Toole, David D	Officer	CFO	Direct	Purchase	2,000	10.28	$20,560.00	15,000	4
2023-11-16	O'Toole, David D	Officer	CFO	Direct	Purchase	1,000	12.15	$12,150.00	12,000	4
2023-11-14	O'Toole, David D	Officer	CFO	Direct	Purchase	1,000	12.88	$12,880.00	10,000	4
2023-08-21	Shiroma, Donna	Officer	General Counsel	Direct	Sale	4,193	15.84	$66,417.12	42,257	4
2023-08-16	O'Toole, David D	Officer	CFO	Direct	Purchase	2,000	17.06	$34,120.00	9,000	4
2023-08-15	O'Toole, David D	Officer	CFO	Direct	Purchase	5,000	17.93	$89,650.00	7,000	4
2023-06-20	O'Toole, David D	Officer	CFO	Direct	Purchase	1,000	16.15	$16,150.00	2,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

151.52%

Inst. Shares: 46,276,871

Shares Outstanding: 30,540,872

2025-12-31

17.26%

Inst. Shares: 4,807,595

Shares Outstanding: 27,860,784

2025-09-30

17.88%

Inst. Shares: 5,077,754

Shares Outstanding: 28,393,445

2025-06-30

28.84%

Inst. Shares: 7,605,090

Shares Outstanding: 26,367,548

2025-03-31

26.63%

Inst. Shares: 6,990,387

Shares Outstanding: 26,253,565

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	46,276,871	30,540,872	151.52%
2025-12-31	4,807,595	27,860,784	17.26%
2025-09-30	5,077,754	28,393,445	17.88%
2025-06-30	7,605,090	26,367,548	28.84%
2025-03-31	6,990,387	26,253,565	26.63%
2024-12-31	6,350,195	25,883,056	24.53%
2024-09-30	6,031,291	25,983,929	23.21%
2024-06-30	6,060,439	25,760,278	23.53%
2024-03-31	7,212,503	25,637,783	28.13%
2023-12-31	6,947,981	25,331,264	27.43%
2023-09-30	7,997,996	25,401,754	31.49%
2023-06-30	7,421,046	25,239,723	29.40%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

AVITA Medical, Inc. (RCEL) — SEC Financial Statements & Analysis

AVITA Medical, Inc. (RCEL) is a surgical & medical instruments & apparatus company, incorporated in DE. AVITA Medical, Inc. trades on Nasdaq, OTC as: RCEL, AVHHL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), AVITA Medical, Inc. reported a 0.98% year-over-year revenue growth, a Gross Profit Margin of 82.37% (TTM), a Debt-to-Equity ratio of -2.72x, a Price-to-Sales (P/S) ratio of 1.70x (TTM), a Price-to-Book (P/B) ratio of -4.56x (TTM), at a market cap of $127.00M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 0.98%
Gross Profit Margin TTM: 82.37%
Debt To Equity: -2.72x
P/S TTM: 1.70x
P/B TTM: -4.56x
Market Cap: $127.00M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is AVITA Medical, Inc. in?

AVITA Medical, Inc. (RCEL) operates in the Surgical & Medical Instruments & Apparatus industry.

What is RCEL's market cap?

AVITA Medical, Inc. (RCEL) has a market capitalization of $127.00M as of 2026-06-30.

What exchange does RCEL trade on?

AVITA Medical, Inc. (RCEL) trades on the Nasdaq, OTC.

Where is AVITA Medical, Inc. incorporated?

AVITA Medical, Inc. is incorporated in DE.